This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Astellas Institute for Regenerative Medicine
Astellas Institute for Regenerative Medicine (AIRM), a subsidiary of Astellas Pharma Inc., is a pioneering entity in the field of regenerative medicine, headquartered in the United States. Established in 2007, AIRM focuses on developing innovative cell therapies aimed at addressing unmet medical needs, particularly in the areas of oncology and rare diseases. With a commitment to advancing scientific research, AIRM has achieved significant milestones, including the development of unique cell-based therapies that leverage cutting-edge technology. The institute's core offerings include advanced cell therapy products that stand out for their potential to transform patient outcomes. Recognised for its contributions to the regenerative medicine landscape, AIRM continues to solidify its market position through strategic partnerships and a robust pipeline of therapeutic candidates, driving forward the future of healthcare.
DitchCarbon Score
How does Astellas Institute for Regenerative Medicine's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Astellas Institute for Regenerative Medicine's score of 50 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Astellas Institute for Regenerative Medicine, headquartered in the US, currently does not report specific carbon emissions data for the most recent year. The organisation's climate commitments and reduction initiatives are inherited from its parent company, Astellas Pharma Inc., at a cascade level of 2. As of now, there are no documented reduction targets or significant achievements in emissions reduction specific to Astellas Institute for Regenerative Medicine. The absence of emissions data and reduction initiatives suggests a need for further development in their climate strategy. The climate commitments and targets from Astellas Pharma Inc. may influence the subsidiary's future actions, but specific details on these initiatives are not provided. Overall, Astellas Institute for Regenerative Medicine is positioned within a broader corporate framework that may guide its environmental impact strategies moving forward.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2005 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 108,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Astellas Institute for Regenerative Medicine is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
